Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 279 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Arginine-hydrochloride Clear all
Completed Phase 2 Interventional Results available

Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers

NCT00004412
View directory record Official record
Conditions
Skin Ulcers, Sickle Cell Anemia
Interventions
Arginine Butyrate, Standard local care dressing
Drug · Other
Lead sponsor
Susan P. Perrine
Other
Eligibility
16 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 5, 2026, 5:51 PM EDT
Completed Not applicable Interventional

Treatment and Management of Women With Bleeding Disorders

NCT00111215
View directory record Official record
Conditions
Menorrhagia, Blood Coagulation Disorders, Blood Platelet Disorders, Von Willebrand Disease, Hematologic Disease
Interventions
Tranexamic Acid, Desmopressin Acetate
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
6
States / cities
Atlanta, Georgia • East Lansing, Michigan • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2007 · Synced Oct 5, 2026, 5:51 PM EDT
Completed Phase 1 Interventional

Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus

NCT00006340
View directory record Official record
Conditions
Leukemia, Lymphoma, Precancerous Condition, Small Intestine Cancer
Interventions
arginine butyrate, ganciclovir
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
3
States / cities
Indianapolis, Indiana • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 5, 2026, 5:51 PM EDT
Recruiting Phase 1 Interventional

Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)

NCT06280482
View directory record Official record
Conditions
Smooth Muscle Dysfunction Syndrome (SMDS)
Interventions
Nicotinamide riboside (NR)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Year and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 5, 2026, 5:51 PM EDT
Completed Phase 1 Interventional

Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers

NCT02506023
View directory record Official record
Conditions
Hemophilia A
Interventions
Desmopressin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Oct 5, 2026, 5:51 PM EDT
Enrolling by invitation Not applicable Interventional

Impact of an Arginine-containing Toothpaste on the Subgingival Microbiota in Patients in Supportive Periodontal Care

NCT07755800
View directory record Official record
Conditions
Gum Disease
Interventions
Arginine Toothpaste, Fluoride Toothpaste
Device
Lead sponsor
Sukirth M Ganesan, BDS, PhD
Other
Eligibility
18 Years to 95 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 5, 2026, 5:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Examine the Effect of a Thermogenic Energy Drink in Healthy Adults

NCT05061797
View directory record Official record
Conditions
Metabolism
Interventions
Thermogenic Energy Drink - Active Study Product Formula, Placebo
Dietary Supplement
Lead sponsor
Rowdy Energy
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 5, 2026, 5:51 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Effects of an Antioxidant Supplement on Blood Vessel Health

NCT06424756
View directory record Official record
Conditions
Healthy
Interventions
MitoQ, Placebo, MitoTempo, Tempol, L-NAME, SNP - Sodium Nitroprusside
Dietary Supplement · Drug
Lead sponsor
University of Georgia
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 5, 2026, 5:51 PM EDT
Completed Phase 1 Interventional

Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer

NCT02101580
View directory record Official record
Conditions
Advanced Pancreatic Cancer
Interventions
ADI-PEG 20
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 5, 2026, 5:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Supplementation Trial on Arginine With Metabolic Profiling

NCT03409380
View directory record Official record
Conditions
Protein, Amino Acid, Arginine
Interventions
Arginine Drink, Plain Drink
Dietary Supplement
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 39 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 5, 2026, 5:51 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Prandial Metabolic Phenotype in Adults

NCT05400733
View directory record Official record
Conditions
Protein Metabolism
Interventions
Total Amino Acids, Essential Amino Acids, Essential Amino Acids + Hydroxy-methylbutyric acid (HMB), Essential Amino Acids + Leucine, Essential Amino Acids High, Placebo Water
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
60 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 5, 2026, 5:51 PM EDT
Completed Phase 1 Interventional

Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme

NCT02017249
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
arginine in powder form, Silica and cellulose placebo powder
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 5, 2026, 5:51 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area

NCT03548064
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli, Immunisation
Interventions
Placebo, Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 5, 2026, 5:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Plasma Triglyceride Extraction by The Muscle

NCT01860911
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Insulin, NG-monomethyl-L-arginine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 5, 2026, 5:51 PM EDT
Completed Phase 1 Interventional

Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease

NCT00072826
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Oxypurinol, L-NMMA, Acetylcholine
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 5, 2026, 5:51 PM EDT
Terminated Phase 1 Interventional

Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

NCT02029690
View directory record Official record
Conditions
Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced, Non-squamous Non-small Cell Lung Carcinoma, Uveal Melanoma, Hepatocellular Carcinoma, Glioma, Sarcomatoid Carcinoma
Interventions
ADI-PEG 20
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 5, 2026, 5:51 PM EDT
Completed Phase 1 Interventional

Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma

NCT03922880
View directory record Official record
Conditions
Uveal Melanoma
Interventions
ADI PEG20, Nivolumab, Ipilimumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 5, 2026, 5:51 PM EDT
Completed Not applicable Interventional

L-arginine for Prevention of Kidney Damage in Liver Transplant Recipients

NCT00587418
View directory record Official record
Conditions
Liver Transplant Recipients
Interventions
L-arginine, Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 5, 2026, 5:51 PM EDT
Completed Phase 1 Interventional Results available

Phase Ib of L-NMMA and Pembrolizumab

NCT03236935
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma Bladder, DNA Repair-Deficiency Disorders
Interventions
L-NMMA, Pembrolizumab
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 5, 2026, 5:51 PM EDT
Completed Phase 1 Interventional

Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer

NCT01497925
View directory record Official record
Conditions
Solid Tumors, Prostate Cancer
Interventions
ADI-PEG 20
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 5, 2026, 5:51 PM EDT
Completed Phase 2 Interventional Results available

Arginine Therapy for Sickle Cell Disease Pain

NCT02536170
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Pain Episode
Interventions
L-arginine, L-arginine Loading Dose, Placebo
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
3 Years to 21 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 5, 2026, 5:51 PM EDT
Completed Not applicable Interventional

A Home-based Lifestyle Intervention for Optimizing Surgical Outcomes Among Urinary Bladder Cancer Patients

NCT06002269
View directory record Official record
Conditions
Bladder Cancer, Cystectomy, Chemotherapy
Interventions
Dietary and Exercise Intervention
Combination Product
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 5, 2026, 5:51 PM EDT
Withdrawn No phase listed Observational

Proline Metabolism in Severely Burned Patients: Effect of Modulated Parenteral Feeding

NCT00216983
View directory record Official record
Conditions
Burns
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 5, 2026, 5:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers

NCT03031535
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
Intranasal octreotide acetate, Subcutaneous octreotide acetate, Growth hormone-releasing hormone, Arginine hydrochloride
Drug · Diagnostic Test
Lead sponsor
Dauntless Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 5, 2026, 5:51 PM EDT